Axsome Therapeutics, Inc.
https://axsome.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Axsome Therapeutics, Inc.
Lundbeck And Axsome Rival Candidate Data Raise Prospects For First Alzheimer’s Agitation Approvals
The firms unveiled positive Phase III data from their respective assets for treating the agitation seen in Alzheimer’s disease with Lundbeck’s candidate set to become first-to-market for the challenging behavioral symptom.
Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
Relmada’s Phase III Depression Study Scuppered By ‘Placebo Paradox’
An unexpectedly strong response in the placebo arm has derailed a monotherapy study of Relmada’s investigational antidepressant REL-1017, but the company will continue its trials as an adjunctive therapy.
Pfizer Leads Big Pharma M&A In 2022 – But Is There More To Come?
Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals